🟢 HELP is trading 9.3% up today after pricing $50M offering to fund Phase 3 trial

HELP is trading 9.3% up now at $5.30 after the company priced a $50 million underwritten public offering at $4.85 per share.

• The capital raise will fund late-stage development of lead depression and anxiety programs and provide capital for general corporate purposes.
• The successful pricing appears to reassure investors regarding Helus Pharma’s ability to finance its critical Phase 3 APPROACH trial.
• Shares showed immediate strength following the announcement, previously climbing 9.1% to $5.29 during pre-market trading.